Welcome to our dedicated page for Atossa Therapeutics news (Ticker: ATOS), a resource for investors and traders seeking the latest updates and insights on Atossa Therapeutics stock.
Atossa Therapeutics, Inc. develops clinical-stage medicines for oncology and other areas of unmet medical need. Its recurring news centers on (Z)-endoxifen, the company's lead product candidate, including breast cancer research, mammographic breast density data, and expansion into rare disease indications such as Duchenne muscular dystrophy and McCune-Albright Syndrome.
Company updates also cover FDA orphan and rare pediatric disease designations, clinical and preclinical data presentations, peer-reviewed publications, intellectual property developments, leadership additions, financial results, and capital-allocation commentary tied to Atossa's development strategy.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced an expanded research agreement with Weill Cornell Medicine to explore the synergy between antibody drug conjugates (ADCs) and (Z)-endoxifen in oncology, particularly breast cancer. The partnership aims to validate in silico research showing enhanced anti-tumor effects when combining (Z)-endoxifen with ADCs. Seven key opinion leaders support this approach for patients with advanced breast cancer. The research will focus on FDA-approved ADCs, TRODELVY® and ENHERTU®, currently used in monotherapies for metastatic breast cancer.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.